| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 | | OMB APPROVAL | | OMB Number: | 3235-0104 | | Expires: | December 31, 2014 | | Estimated average burden | | hours per response | 0.5 |
|
|
1. Name and Address of Reporting Person*
| 950 TOWER LANE, SUITE 900 | |
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2012 | 3. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC
[SCLN]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable) | Director | | 10% Owner | | X | Officer (give title below) | | Other (specify below) | | VP, Finance and Controller |
| 5. If Amendment, Date of Original Filed (Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X | Form filed by One Reporting Person | | Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
| 2.
Amount of Securities Owned (Instr.
4)
| 3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
| 4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
|---|
|
Common Stock
|
2,000
|
D
| |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) |
|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year)
| 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Excercise Price of Derivative Security
| 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)
| 6. Nature of Indirect Beneficial Ownership (Instr. 5)
|
|---|
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
|---|
|
Incentive Stock Option (right to buy)
| | 04/05/2021 |
Common Stock
|
35,000
|
$
4.17
|
D
| |
|
lncentive Stock Option (right to buy)
| | 09/10/2019 |
Common Stock
|
50,000
|
$
5.02
|
D
| |
|
Non-Qualified Stock Option (right to buy)
| | 03/15/2022 |
Common Stock
|
50,000
|
$
6.22
|
D
| |
|
Restricted Stock Unit
| | |
Common Stock
|
15,000
|
$
|
D
| |
| Explanation of Responses: |
|
|
|
|
|
|
|
| /s/ Stephanie Wong | 08/10/2012 |
| ** Signature of Reporting Person | Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
rrd316520_357631.html
LIMITED POWER OF ATTORNEY
FOR SECTION 16(a) REPORTING
KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby
makes, constitutes and appoints Friedhelm Blobel, Ph.D. and Gary S. Titus, and
each of them, as the undersigneds true and lawful attorney-in-fact (the
Attorney-in Fact), with full power of substitution and resubstitution, each with
the power to act alone for the undersigned and in the undersigneds name, place
and stead, in any and all capacities to:
1. prepare, execute, deliver and file with the United States
Securities and Exchange Commission, any national securities exchange and
SciClone Pharmaceuticals, Inc. (the Company) any and all reports (including any
amendment thereto) of the undersigned required or considered advisable under
Section 16(a) of the Securities Exchange Act of 1934, as amended (the Exchange
Act), and the rules and regulations thereunder, with respect to the equity
securities of the Company, including Form 3 (Initial Statement of Beneficial
Ownership of Securities), Form 4 (Statement of Changes in Beneficial Ownership),
and Form 5 (Annual Statement of Changes in Beneficial Ownership); and
2. seek or obtain, as the undersigneds representative and on the
undersigneds
behalf, information on transactions in the Companys equity
securities from any third party, including the Company, brokers, dealers,
employee benefit plan administrators and trustees, and the undersigned hereby
authorizes any such third party to release any such information to the
Attorney-in-Fact.
The undersigned acknowledges that:
1. this Limited Power of Attorney authorizes, but does not require,
the Attorney-in-Fact to act at his or her discretion on information provided to
such Attorney-in-Fact without independent verification of such information;
2. any documents prepared and/or executed by the Attorney-in-Fact on
behalf of the undersigned pursuant to this Limited Power of Attorney will be in
such form and will contain such information as the Attorney-in-Fact, in his or
her discretion, deems necessary or desirable;
3. neither the Company nor the Attorney-in-Fact assumes any
liability for the undersigneds responsibility to comply with the requirements of
Section 16 of the Exchange Act, any liability of the undersigned for any failure
to comply with such requirements, or any liability of the undersigned for
disgorgement of profits under Section 16(b) of the Exchange Act; and
4. this Limited Power of Attorney does not relieve the undersigned
from responsibility for compliance with the undersigneds obligations under
Section 16 of the Exchange Act, including, without, limitation, the reporting
requirements under Section 16(a) of the Exchange Act.
The undersigned hereby grants to the Attorney-in-Fact full power and
authority to do and perform each and every act and thing requisite, necessary or
convenient to be done in connection with the foregoing, as fully, to all intents
and purposes, as the undersigned might or could do in person, hereby ratifying
and confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Limited
Power of Attorney.
This Limited Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 or 5 with respect
to the undersigneds holdings of and transactions in equity securities of the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Attorney-in-Fact.
This Limited Power of Attorney shall be governed and construed in
accordance the laws of the State of California without regard to the
laws that might otherwise govern under applicable principles of conflicts of
laws thereof.
IN WITNESS WHEREOF, the undersigned has caused this Limited Power of
Attorney to be executed as of August 7, 2012.
Signature: /s/ Stephanie Wong
-----------------------
Print Name: Stephanie Wong